- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00482612
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) (RUBY)
September 4, 2018 updated by: Merck Sharp & Dohme LLC
A Two-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Efficacy and Safety Out-Patient Trial With Org 50081 in Patients With Chronic Primary Insomnia
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia.
It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries relative to placebo.
Study Overview
Study Type
Interventional
Enrollment (Actual)
526
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Has signed written informed consent after the scope and nature of the investigation was explained to them
- Has difficulty falling asleep, maintaining sleep or has early morning awakenings
Exclusion Criteria:
- Significant medical or psychiatric illness causing sleep disturbances
- Has a history of bipolar disorder or family (immediate family) of suicide
- Has sleep disorder such as sleep related breathing disorder, restless leg syndrome, narcolepsy
- Has significant other medical illness such as acute or chronic pain, heart, kidney or liver disease within the last year
- Currently diagnosed or meets the criteria for Major Depressive Disorder (MDD) or has been treated for MDD with the last 2 years
- Substance abuse, excessive use of alcohol (as determined by the physician) or drug addiction within the last year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Esmirtazapine 1.5 mg
Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
|
Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound.
In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate.
Tablets were administered orally once daily about 30 minutes prior to bedtime.
Other Names:
|
|
EXPERIMENTAL: Esmirtazapine 3.0 mg
Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
|
Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound.
In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate.
Tablets were administered orally once daily about 30 minutes prior to bedtime.
Other Names:
|
|
EXPERIMENTAL: Esmirtazapine 4.5 mg
Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
|
Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound.
In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate.
Tablets were administered orally once daily about 30 minutes prior to bedtime.
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
Placebo to esmirtazapine
|
Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate.
Tablets were administered orally once daily about 30 minutes prior to bedtime.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period
Time Frame: Day 1 to Day 15
|
TST was defined as the total amount of time (measured in minutes) that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary.
TST values over the 14-day active treatment period were averaged for each participant, and average TST was then reported by treatment arm.
For participants with missing data, the average of the nights for which TST data were present was used in the analysis.
|
Day 1 to Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Sleep Latency (SL) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period
Time Frame: Day 1 to Day 15
|
SL was defined as the duration of time measured in minutes that it took a participant to fall asleep as recorded daily in the participant's sleep diary.
SL values over the 14-day active treatment period were averaged for each participant, and average SL was then reported by treatment arm.
For participants with missing data, the average of the nights for which TST data were present were used in the analysis.
|
Day 1 to Day 15
|
|
Number of Participants Experiencing an Adverse Event (AE) During the 14-day In-treatment Period
Time Frame: Day 1 to Day 15
|
The total number of participants with an AE during the 14-day In-treatment Period was tallied for each treatment arm.
An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
|
Day 1 to Day 15
|
|
Number of Participants Who Discontinued From Study Treatment Due to an AE During the 14-day In-Treatment Period
Time Frame: Day 1 to Day 15
|
The total number of participants discontinuing from study treatment due to experiencing an AE was tallied for each treatment arm.
An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
|
Day 1 to Day 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 7, 2006
Primary Completion (ACTUAL)
August 11, 2008
Study Completion (ACTUAL)
August 11, 2008
Study Registration Dates
First Submitted
June 1, 2007
First Submitted That Met QC Criteria
June 4, 2007
First Posted (ESTIMATE)
June 5, 2007
Study Record Updates
Last Update Posted (ACTUAL)
October 3, 2018
Last Update Submitted That Met QC Criteria
September 4, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Adrenergic alpha-Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Mirtazapine
Other Study ID Numbers
- P05706
- 176001 (OTHER: Protocol number)
- MK-8265-003 (OTHER: Protocol number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.